Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
Authors:
- 24 November 2022
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 18 (1) , 169-176
Abstract
Selpercatinib (Retevmo®/Retsevmo®) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC). In a pivotal phase 1/2 clinical trial in this population, selpercatinib treatment was associated with robust and durable responses, including intracranial responses, in patients previously treated with platinum-based chemotherapy, as well as in treatment-naïve patients. Selpercatinib had a manageable tolerability profile and an acceptable safety profile; adverse events could generally be managed with dose reductions and only a small proportion of patients discontinued selpercatinib due to treatment-related adverse events. The most common treatment-related adverse events that were grade 3–4 in severity were hypertension, elevated alanine aminotransferase and elevated aspartate aminotransferase. Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC.Keywords
This publication has 18 references indexed in Scilit:
- Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung CancerCurrent Treatment Options in Oncology, 2021
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 TrialClinical Cancer Research, 2021
- FP14.10 Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLCJournal of Thoracic Oncology, 2021
- Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access programTherapeutic Advances in Medical Oncology, 2021
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerAnnals of Oncology, 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung CancersJournal of Thoracic Oncology, 2018
- Selective RET kinase inhibition for patients with RET-altered cancersAnnals of Oncology, 2018
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryJournal of Clinical Oncology, 2017
- RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012